These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 29978587)

  • 1. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
    Bozkurt M; Yumru AE; Aral I
    Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
    Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
    Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
    Sagi-Dain L; Lavie O; Auslander R; Sagi S
    Int J Biol Markers; 2015 Nov; 30(4):e394-400. PubMed ID: 26109367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound features and clinical outcome of patients with malignant ovarian masses diagnosed during pregnancy: experience of a gynecological oncology ultrasound center.
    Moro F; Mascilini F; Pasciuto T; Leombroni M; Li Destri M; De Blasis I; Garofalo S; Scambia G; Testa AC
    Int J Gynecol Cancer; 2019 Sep; 29(7):1182-1194. PubMed ID: 31326950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging in gynecological disease (11): clinical and ultrasound features of mucinous ovarian tumors.
    Moro F; Zannoni GF; Arciuolo D; Pasciuto T; Amoroso S; Mascilini F; Mainenti S; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2017 Aug; 50(2):261-270. PubMed ID: 28782867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
    Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
    Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging in gynecological disease (13): clinical and ultrasound characteristics of endometrioid ovarian cancer.
    Moro F; Magoga G; Pasciuto T; Mascilini F; Moruzzi MC; Fischerova D; Savelli L; Giunchi S; Mancari R; Franchi D; Czekierdowski A; Froyman W; Verri D; Epstein E; Chiappa V; Guerriero S; Zannoni GF; Timmerman D; Scambia G; Valentin L; Testa AC
    Ultrasound Obstet Gynecol; 2018 Oct; 52(4):535-543. PubMed ID: 29418038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study.
    Sundar S; Agarwal R; Davenport C; Scandrett K; Johnson S; Sengupta P; Selvi-Vikram R; Kwong FL; Mallett S; Rick C; Kehoe S; Timmerman D; Bourne T; Van Calster B; Stobart H; Neal RD; Menon U; Gentry-Maharaj A; Sturdy L; Ottridge R; Deeks J;
    Lancet Oncol; 2024 Oct; 25(10):1371-1386. PubMed ID: 39362250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer.
    Li M; Tan J; Zhang Y; Ai C; Wang H; Zhang H; Jin Y; Chen Y
    Abdom Radiol (NY); 2021 Jun; 46(6):2367-2375. PubMed ID: 32424610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
    Li W; Wang D
    Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
    Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
    Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.